Hao-Yuan Chuang Sells 367 Shares of Belite Bio (NASDAQ:BLTE) Stock

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) CFO Hao-Yuan Chuang sold 367 shares of Belite Bio stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $180.35, for a total value of $66,188.45. Following the completion of the sale, the chief financial officer directly owned 93,433 shares in the company, valued at $16,850,641.55. This represents a 0.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Belite Bio Stock Performance

NASDAQ BLTE opened at $162.80 on Friday. The business has a fifty day moving average price of $152.50 and a 200 day moving average price of $159.86. Belite Bio, Inc. Sponsored ADR has a one year low of $60.00 and a one year high of $200.00. The company has a market cap of $6.53 billion, a P/E ratio of -59.63 and a beta of -1.22.

Belite Bio (NASDAQ:BLTE) last announced its quarterly earnings data on Tuesday, June 30th. The company reported ($0.54) earnings per share for the quarter. As a group, sell-side analysts predict that Belite Bio, Inc. Sponsored ADR will post -3.17 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in BLTE. Darwin Global Management Ltd. acquired a new stake in shares of Belite Bio in the fourth quarter valued at $486,915,000. RA Capital Management L.P. acquired a new position in Belite Bio during the 3rd quarter worth about $64,750,000. RTW Investments LP lifted its stake in Belite Bio by 128.9% during the 4th quarter. RTW Investments LP now owns 715,332 shares of the company’s stock worth $114,425,000 after acquiring an additional 402,832 shares in the last quarter. Millennium Management LLC boosted its holdings in Belite Bio by 2,594.6% during the 4th quarter. Millennium Management LLC now owns 558,882 shares of the company’s stock valued at $89,399,000 after acquiring an additional 538,141 shares during the period. Finally, Perceptive Advisors LLC boosted its holdings in Belite Bio by 732.0% during the 4th quarter. Perceptive Advisors LLC now owns 414,239 shares of the company’s stock valued at $66,262,000 after acquiring an additional 364,451 shares during the period. 0.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on BLTE shares. Benchmark restated a “buy” rating on shares of Belite Bio in a research report on Friday. Zacks Research upgraded shares of Belite Bio from a “hold” rating to a “strong-buy” rating in a report on Monday, July 20th. Truist Financial set a $217.00 target price on shares of Belite Bio in a research note on Friday, May 22nd. Cantor Fitzgerald upped their price target on Belite Bio from $266.00 to $270.00 and gave the company an “overweight” rating in a research report on Wednesday. Finally, Morgan Stanley increased their price target on Belite Bio from $201.00 to $206.00 and gave the company an “overweight” rating in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $205.80.

Trending Headlines about Belite Bio

Here are the key news stories impacting Belite Bio this week:

• Positive Sentiment: Quarterly loss was narrower than expected. Belite Bio reported second-quarter 2026 EPS of -$0.54, beating the analyst consensus of -$0.73 by $0.19. The earnings surprise may support the stock by suggesting better-than-expected cost control or operating performance. Belite Bio quarterly earnings results
• Positive Sentiment: HC Wainwright sees substantial upside potential. The research firm issued a bullish forecast for BLTE, which could improve investor sentiment toward Belite Bio’s pipeline and long-term prospects. The report’s headline did not provide a specific price target in the available information. HC Wainwright forecast for Belite Bio
• Neutral Sentiment: Management provided a second-quarter financial and corporate update. Belite Bio released unaudited results for the quarter ended June 30, 2026, and discussed its business as it advances therapies for degenerative retinal diseases. Investors will likely focus on pipeline milestones, regulatory progress and cash resources from the update. Belite Bio second-quarter 2026 results and corporate update
• Negative Sentiment: CEO and CFO both sold small portions of their holdings. CEO Yu-Hsin Lin sold 365 shares and CFO Hao-Yuan Chuang sold 367 shares at an average price of $180.35. The transactions reduced their direct holdings by only 0.21% and 0.39%, respectively, limiting the significance, but simultaneous executive sales can still create a modest negative sentiment signal. Belite Bio CEO insider sale filing

About Belite Bio

Belite Bio, Inc (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.